Figure S19 and references for supplementary figures from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

<p>Factors associated with resistance to idelalisib in cell lines are expressed in clinical specimens. Expression levels of genes related to idelalisib resistance were studied across different subtypes of B cell lymphoma: (A) n=48 (5), (B) n=80 (6). B-CLL: chronic lymphocytic leukemia, B.FL: follicular lymphoma, LBNH: non-specified non-Hodgkin B cell lymphoma, MALT: MZL of the mucosa associated tissue, MCL: Mantle cell lymphoma, NMZL: nodal marginal zone lymphoma, SMZL: splenic marginal zone lymphoma. Expression levels of genes related to idelalisib resistance were studied across the subtypes of diffuse large B cell lymphoma (DLBCL, two series: (C) n=181 and (D) n=223 from GSE10846 (7). ABC: activated B cell like DLBCL, GCB: germinal center B cell like DLBCL, type3: type3 DLBCL. Red for highly expressed gene in B cells (CD79A), blue for not expressed gene in B cells (IGFBP1), black for the gene of interest. (E) Gene set enrichment analyses comparing resistant versus parental for the top-200 genes positively correlated genes with HBEGF in SMZL clinical specimens (6). NES: normalized enrichment score, p-val: nominal p-value, FDR: false discovery rate.</p>